Panitumumab

DEA Class; Rx

Common Brand Names; Vectibix

• Antineoplastics, Monoclonal Antibody; 
• Antineoplastics, EGFR Inhibitor

Indicated for both KRAS and NRAS as determined by an FDA-approved test for this use (eg, next-generation sequencing [NGS] kit)

Combination therapy: With FOLFOX, as first-line treatment

Monotherapy: Following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy

—

• Erythema (65%)
• Acneiform dermatitis (57%)
• Pruritus (57%)
• Hypomagnesemia (39%)
• Fatigue (26%)
• Abdominal pain (25%)
• Paronychia (25%)
• Skin exfoliation (25%)
• Nausea (23%)
• Rash (22%)
• Constipation (21%)
• Diarrhea (21%)
• Vomiting (21%)
• Skin fissures (20%)
• Cough (14%)
• Dermatologic toxicity, Grade 3 and 4 (14% )
• Acne (13%)
• Peripheral edema (12%)

Increased tumor progression, increased mortality, or lack of benefit in patients with RAS-mutant mCRC; determine RAS-mutant tumor status in an experienced laboratory using an FDA-approved test before treatment

Monitor patients who develop dermatologic toxicities while receiving panitumumab for the development of inflammatory or infectious sequelae; limit sun exposure

Panitumumab is not indicated for use in combination with chemotherapy due to increase in mortality or toxicity

Permanently discontinue in patients developing pulmonary fibrosis/interstitial lung disease

Monitor electrolytes and institute appropriate treatment if needed

Terminate the infusion for severe infusion reactions

Ocular toxicities reported; monitor for keratitis or ulcerative keratitis; interrupt or discontinue for acute or worsening keratitis

Discontinue permanently if patient develops interstitial lung disease, pneumonitis, or lung infiltrates

Avoid pregnancy

Not indicated for treatment of patients with colorectal cancer that harbor somatic RAS mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146) of either KRAS or NRAS (RAS)

Progressively decreasing serum magnesium levels leading to severe (grade 3-4) hypomagnesemia reported; monitor patients for hypomagnesemia and hypocalcemia prior to initiating treatment, periodically during treatment, and for up to 8 weeks after completion of treatment; other electrolyte disturbances, including hypokalemia, have also been observed; replete magnesium and other electrolytes as appropriate

Based on data from animal studies and mechanism of action; therapy can cause fetal harm when administered to pregnant women

There are no data on presence of drug in human milk or effects of panitumumab on breastfed infant or on milk production

Panitumumab

injectable solution

• 100mg/5mL